IAIan Arnott

Ian Arnott

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ian Arnott has a total of 144 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The 2026 IBD UK Standards of healthcare service design and delivery for adults and children living with Crohn’s disease and ulcerative colitis

    by Christopher A Lamb, Catherine Picton, Ian Arnott, Pearl Avery, Debra Attwood, Saswata Banerjee, Sarah Bayliss, Graham Bell, Gauraang Bhatnagar, Caroline Brocklehurst, et al.

    Objective: Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, requires consistent high-quality care to reduce variation in patient experience and improve outcomes. The IBD Standards previously published in 2009, 2013 and 2019 have provided an aspirational framework for best practice. Since 2019, two rounds of national benchmarking with patient engagement, healthcare professional (HCP) consultation and new evidence have highlighted areas for quality improvement (QI). We aimed to develop the 2026 IBD UK Standards of healthcare for adults and children, ensuring they reflect current and aspirational best practice and to support future QI initiatives. Methods: A multidisciplinary working group of 18 HCPs and 4 people with lived experience assessed the 59 IBD standards from 2019, categorising them as needing no change, minor or major amendment or deletion. New standards were developed through iterative drafting and consensus review, with feedback incorporated from 47 external HCPs and a patient workshop. The 2026 standards remain aspirational, structured across seven domains: the IBD service, pre-diagnosis, newly diagnosed, flare management, surgery, inpatient care and ongoing care. Results: The 2026 IBD UK Standards comprise 60 statements: 6 unchanged from 2019, 48 updated, 7 deleted and 6 new. Key themes include multidisciplinary, coordinated care with defined leadership; age-appropriate transition pathways; timely referral from primary care, access to diagnostic tests, treatments and surgery; patient-centred care, including better communication, personalised care plans, shared decision-making and support for self-management; holistic assessment and management of physical, nutritional and psychological need; QI and audit supported by electronic systems; research participation and innovation. Conclusions: The 2026 IBD UK Standards provide a contemporary aspirational framework to drive consistent, high-quality, personalised care across the UK. They aim to reduce inequality, improve experience and outcomes through support for patient-centred shared decision-making, national benchmarking, service development, patient involvement and QI.


  • Open Access

    Comparative analysis of inflammatory bowel disease (IBD) patient- and service-reported quality of care using 2019 and 2023 UK benchmarking data from more than 26 000 adult patient respondents and 154 IBD services

    by A Barney Hawthorne, Paul Christiansen, Ian Arnott, Fraser Cummings, Liz Dobson, Alexandra Kent, Jimmy K Limdi, Robert J Mulligan, Gareth C Parkes, Fiona Rees, et al.

    Introduction: The IBD UK Benchmarking surveys, conducted in 2019 and 2023, collected repeated data regarding the quality of inflammatory bowel disease (IBD) care across the UK using both service self-assessments and patient-reported experience measures (PREMs). We aimed to assess variation between patient and provider perspectives. Methods: All UK hospitals offering specialist IBD services were invited to complete online surveys. Patients were invited through social media, charities, and clinical services. This study compared changes over the 4 years and examined alignment between healthcare-reported and patient-reported assessments. Results: From 26 760 patient responses and 154 service assessments, patient-perceived care quality (PPCQ) declined between 2019 and 2023 (P < .001). Male sex and older age were associated with higher PPCQ. Greater disease severity was associated with lower PPCQ (P < .001). More patients reported IBD symptoms to impact activities of daily living in 2023 (P < .001). Factors associated with higher PPCQ included rapid diagnosis, being supported by an IBD team, and having knowledgeable IBD nurses. Access, information, communication, and empowerment were identified by patients as needing improvement (P < .001). Services with lowest quartile quality scores in 2019 demonstrated significant improvement over time, whilst those with highest 2019 scores demonstrated significant deterioration in PPCQ (P < .001). Services reported better performance than patients (P < .001). Conclusions: These data underscore the importance of assessing lived experience and the care quality perception gap between patients and service providers. Regular benchmarking including PREMs should be used to drive and assess service-level, national and international quality improvement initiatives.


  • Open Access

    Twenty‐Year Trends in Colectomy Rates and Advanced Therapy Prescribing in Lothian, Scotland

    by Alexander T. Elford, Nathan Constantine‐Cooke, Phil W. Jenkinson, Beatriz Gros, Nikolas Plevris, Mathew Lyons, Solomon Ong, Neil Greenlees, Victor Velasco‐Pardo, Claire O'HAre, et al.

    Background: The impact of advanced therapy prescribing on colectomy rates in ulcerative colitis (UC) is unknown with conflicting published evidence.Aim: To describe advanced therapy prescribing trends and colectomy rates for patients with UC in Lothian, UK between January 1st, 2004 and December 31st, 2023.Methods: We obtained incidence and prevalence data from the Lothian IBD Registry, a rigorously validated population cohort. We report advanced therapy prescribing and colectomy data as raw numbers and annual incidence rates. We used piecewise linear regression analyses to identify temporal trends in prescription and colectomy rates.Results: The prevalence of UC increased from 216 to 441 per 100,000 population in the 20 years from 2004, culminating in a total of 4115 patients with UC in 2023. We identified 720 patients who had received an advanced therapy. Prescribing of first‐line advanced therapy increased from 0 in 2004 to 115 in 2023, equating to 0.00 and 2.82 per 100 patients with UC. We identified 563 patients of the prevalent UC population who had colectomy, of whom 68% were performed as emergencies. Absolute colectomy numbers decreased from 42 in 2004 to 7 in 2023, equating to 2.48 and 0.22 per 100 patients with UC. A join point in 2013 was found for both increased advanced therapy prescribing and decreased colectomy rates.Conclusion: The incidence of colectomy in the UC population has decreased over time while the use of advanced therapies has greatly increased.


  • Validation of the ACE [Albumin, CRP, and Endoscopy] Index in Acute Colitis: Analysis of the CONSTRUCT dataset

    by Rebecca K Grant, Gareth-Rhys Jones, Nikolas Plevris, Ruairi W Lynch, William M Brindle, Hayley A Hutchings, John G Williams, Laith Alrubaiy, Alan Watkins, Charlie W Lees, et al.

    In 2020 we reported the ACE Index in Acute Colitis which used biochemical and endoscopic parameters to predict steroid non-response on admission in patients with acute ulcerative colitis (UC). We aimed to validate the ACE Index in an independent cohort. The validation cohort comprised the patients screened as eligible for inclusion in the CONSTRUCT study, a prospective, randomised, placebo-controlled trial which compared the effectiveness of treatment with infliximab versus ciclosporin in patients admitted with acute UC. The CONSTRUCT cohort database was reviewed at The Edinburgh IBD Unit and the same biochemical and endoscopic variables and cut-off values as those in the derivation cohort were applied to the validation cohort. In total, 800 patients were identified. 62.5% (55/88) of patients with a maximum ACE Index of 3 did not respond to IV steroids (positive predictive value (PPV) 62.5%, negative predictive value (NPV) 79.8%). Furthermore, 79.8% (158/198) of patients with an ACE Index of 0 responded to IV steroids (PPV 79.8%, NPV 62.5%). Receiver Operator Characteristic (ROC) curve analysis produced an Area Under the Curve (AUC) of 0.663 (p=<0.001). We have now reported and externally validated the ACE Index in Acute Colitis in a combined cohort of over 1000 patients from across the United Kingdom. The ACE Index may be used in conjunction with clinical judgement to help identify patients admitted with active UC who are at high risk of not responding to IV steroids. Further studies are required to improve objectivity and accuracy of assessment.


  • Enhancing Your Employability

    by Ian Arnott, Michelle M. Carney

    The sports sector is incredibly competitive as is the events industry, and therefore, those looking to break into the sector, particularly graduates, have an uphill task in demonstrating why they should be considered for roles in highly competitive environments. This is especially challenging in the sports sector as there isn't a particularly high churn rate, and those that do leave jobs tend to stay in the sector, therefore reducing the number of entry level positions. However, there is good news. The COVID-19 pandemic has accelerated the need for digitisation across all sectors, and the parts of the sports sector that have been lagging in the digital revolution are having to urgently review systems and processes and how sport is delivered and consumed. This is where the key opportunities for Gen Z are, as a generation who have grown up with technology, the internet, and social media. Request access from your librarian to read this chapter's full text.

  • Sports Management Industry

    by Ian Arnott

    The issue of employability serves as a life motive of wider social-political changes that have taken place during the past three decades. This period of change has been characterized as the ascendancy of economic instrumentalism over liberal humanism. This shift in policy from the post-war social democratic state towards the neo-liberal polity has led to the redistribution of responsibility from the state to the individual. This is most evident in the emphasis given to vocational education and training by central government in its ‘skills-gap', therefore fulfilling the void at present by ensuring graduates who are fully prepared to enter their workforce without any additional training or experience. Request access from your librarian to read this chapter's full text.

  • Mo1573: RATES, PREDICTIVE FACTORS AND EFFECTIVENESS OF USTEKINUMAB INTENSIFICATION TO 4- OR 6-WEEKLY INTERVALS IN CROHNS’S DISEASE

    by Lauranne Derikx, Nikolas Plevris, Shanna Su, Beatriz Gros, Mathew Lyons, Spyros I. Siakavellas, Nathan Constantine-Cooke, Philip Jenkinson, Claire O’hare, Lynne M. Merchant, et al.

  • Open Access

    Inflammatory bowel disease patient‐reported quality assessment should drive service improvement: a national survey of UK IBD units and patients

    by A. Barney Hawthorne, Jackie Glatter, Jonathan Blackwell, Rachel Ainley, Ian Arnott, Kevin J. Barrett, Graham Bell, Matthew J. Brookes, Melissa Fletcher, Rafeeq Muhammed, et al.

    Summary: Background: Healthcare service provision in inflammatory bowel disease (IBD) is often designed to meet targets set by healthcare providers rather than those of patients. It is unclear whether this meets the needs of patients, as assessed by patients themselves. Aims: To assess patients' experience of IBD and the healthcare they received, aiming to identify factors in IBD healthcare provision associated with perceived high‐quality care.Methods: Using the 2019 IBD standards as a framework, a national benchmarking tool for quality assessment in IBD was developed by IBD UK, comprising a patient survey and service self‐assessment.Results: 134 IBD services and 9757 patients responded. Perceived quality of care was lowest in young adults and increased with age, was higher in males and those >2 years since diagnosis. No hospital services met all the national IBD standards for recommended workforce numbers. Key metrics associated with patient‐reported high‐ quality care were: identification as a tertiary centre, patient information availability, shared decision‐ making, rapid response to contact for advice, access to urgent review, joint medical/surgical clinics, and access to research (all p < 0.001). Higher numbers of IBD nurse specialists in a service was strongly associated with patients receiving regular reviews and having confidence in self‐management and reporting high‐ quality care.Conclusions: This extensive patient and healthcare provider survey emphasises the importance of aspects of care less often measured by clinicians, such as communication, shared decision‐ making and provision of information. It demonstrates that IBD nurse specialists are crucial to meeting the needs of people living with IBD.


  • Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn’s Disease

    by Nikolas Plevris, James Fulforth, Mathew Lyons, Spyros I. Siakavellas, Philip W. Jenkinson, Cher S. Chuah, Laura Lucaciu, Rebecca J. Pattenden, Ian D. Arnott, Gareth-Rhys Jones, et al.


  • Open Access

    Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts

    by Lauranne A A P Derikx, Heather W Dolby, Nikolas Plevris, Laura Lucaciu, Caitlin S Rees, Mathew Lyons, Spyros I Siakavellas, Nathan Constantine-Cooke, Philip Jenkinson, Shanna Su, et al.

    Multiple adalimumab [ADA] biosimilars are now approved for use in inflammatory bowel disease [IBD]; however, effectiveness and safety data remain scarce. We aimed to investigate long-term outcomes of the ADA biosimilar SB5 in IBD patients following a switch from the ADA originator [SB5-switch cohort] or after start of SB5 [SB5-start cohort]. We performed an observational cohort study in a tertiary IBD referral centre. All IBD patients treated with Humira underwent an elective switch to SB5. We identified all these patients in a biological prescription database that prospectively registered all ADA start and stop dates including brand names. Data on IBD phenotype, C-reactive protein [CRP], drug persistence, ADA drug and antibody levels, and faecal calprotectin were collected. In total, 481 patients were treated with SB5, 256 in the SB5-switch cohort (median follow-up: 13.7 months [IQR 8.6–15.2]) and 225 in the SB5-start cohort [median follow-up: 8.3 months [4.2–12.8]). Of the SB5-switch cohort, 70.8% remained on SB5 beyond 1 year; 90/256 discontinued SB5, mainly due to adverse events [46/90] or secondary loss of response [37/90]. In the SB5-start cohort, 81/225 discontinued SB5, resulting in SB5-drug persistence of 60.3% beyond 1 year. No differences in clinical remission [p = 0.53], CRP [p = 0.80], faecal calprotectin [p = 0.40] and ADA trough levels [p = 0.55] were found between baseline, week 26 and week 52 following switch. Injection site pain was the most frequently reported adverse event. Switching from ADA originator to SB5 appeared effective and safe in this study with over 12 months of follow-up.